USANA Health Sciences (NYSE:USNA – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.350-3.000 for the period, compared to the consensus estimate of 2.870. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $934.5 million.
USANA Health Sciences Trading Down 2.4 %
USNA stock traded down $0.79 during trading on Tuesday, reaching $31.90. 439,916 shares of the stock were exchanged, compared to its average volume of 145,134. The firm has a market capitalization of $607.96 million, a price-to-earnings ratio of 11.27, a P/E/G ratio of 0.93 and a beta of 0.87. The business has a 50 day moving average price of $33.73 and a 200-day moving average price of $36.68. USANA Health Sciences has a 1 year low of $30.13 and a 1 year high of $50.32.
USANA Health Sciences (NYSE:USNA – Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. On average, research analysts anticipate that USANA Health Sciences will post 2.45 EPS for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on USANA Health Sciences
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Stories
- Five stocks we like better than USANA Health Sciences
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Earnings Per Share Calculator: How to Calculate EPS
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What is diluted earnings per share (Diluted EPS)?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.